INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Soleno Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - SLNO

Core Viewpoint - A class action lawsuit has been filed against Soleno Therapeutics, Inc. regarding allegations of securities fraud and unlawful business practices related to its product, DCCR [2][3]. Group 1: Class Action Details - Investors who suffered losses from their investment in Soleno are encouraged to contact Pomerantz LLP to join the class action lawsuit [1]. - The deadline to request appointment as Lead Plaintiff is May 5, 2026, for those who purchased Soleno securities during the Class Period [2]. Group 2: Product and Market Impact - Scorpion Capital published a report on August 15, 2025, labeling DCCR as overpriced and potentially unsafe for children, leading to a stock price drop of $5.73 per share, or 7.41%, closing at $71.63 [2][3]. - Following the disclosure of a patient death related to DCCR on September 10, 2025, Soleno's stock fell by $13.49 per share, or 19.21%, to close at $56.72 [3]. - On November 4, 2025, Soleno reported an 8% discontinuation rate of DCCR due to adverse effects, which the CEO attributed to the negative impact of the Scorpion report on the product's launch trajectory [4]. - The stock price further declined by $16.98 per share, or 26.59%, closing at $46.87 on November 5, 2025 [5].